JGJames M. Greene

James M. Greene

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James M. Greene has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A simple mechanistic model for insulin-glucose-glucagon dynamics and its implications for diabetes management

    by Mackenzie Dalton, Emmanuel Asante-Asamani, James Greene

    Insulin and glucose dynamics are tightly regulated by the pancreatic islets of Langerhans, which contain beta cells that produce insulin and alpha cells that produce glucagon. Insulin lowers blood glucose by enabling cells to access glucose for energy, while glucagon raises blood glucose levels by stimulating the liver to produce glucose from non-carbohydrate sources as well as breaking down stored glycogen. Maintaining safe blood glucose levels is crucial, as both high (hyperglycemia) and low (hypoglycemia) levels can lead to life threatening consequences. In this work, a simple three-state mechanistic insulin-glucose-glucagon model is developed and validated using data from pigs subjected to an intravenous glucose tolerance test (IVGTT). The model is then used to investigate glucose and glucagon dynamics in patients administering exogenous insulin, shedding light on the impact of improper diabetes management. The results show that delayed administration of exogenous insulin increases the risk of hypoglycemia by suppressing glucagon production. Furthermore, insulin half-lives of 60 minutes or longer were tested, revealing that such prolonged exogenous insulin activity can suppress glucagon's response to critically low glucose levels. This finding suggests that shorter insulin half-lives may help reduce the risk of hypoglycemic events.


  • Open Access

    Antigen presenting cells play a critical role in determining response to regulatory T cell therapy in type 1 diabetes

    by Mackenzie Dalton, Emmanuel Asante-Asamani, James Greene

    Type 1 diabetes (T1D) is an autoimmune disease in which the immune system attacks pancreatic beta cells, leading to high blood glucose levels and requiring lifelong insulin therapy. There is no cure, and individuals with T1D may face a reduced lifespan of up to 12 years. Defects in regulatory T cells (Tregs) are a key contributor to disease onset and are being explored as a therapeutic avenue. However, the effectiveness of Treg therapy remains uncertain. Research is further limited by the inability to directly observe pancreatic and lymph node activity during the long presymptomatic stage of T1D. In this study, we develop a mathematical model for beta and T cell dynamics. We find both Treg quality and quantity affect disease progression, and that antigen-presenting cell (APC) dynamics play a central role. Notably, Treg therapy combined with APC depletion improves outcomes, especially with strong peptide-induced APC activation.

  • Open Access

    Antigen presenting cells play a critical role in determining response to regulatory T cell therapy in type 1 diabetes

    by Mackenzie Dalton, Emmanuel Asante-Asamani, James M. Greene

    Type 1 diabetes (T1D) is an autoimmune disease in which the immune system attacks pancreatic beta cells, leading to high blood glucose levels and requiring lifelong insulin therapy. There is no cure, and individuals with T1D may face a reduced lifespan of up to 12 years. Defects in regulatory T cells (Tregs) are a key contributor to disease onset and are being explored as a therapeutic avenue. However, the effectiveness of Treg therapy remains uncertain. Research is further limited by the inability to directly observe pancreatic and lymph node activity during the long presymptomatic stage of T1D. In this study, we develop a mathematical model for beta and T cell dynamics. We find both Treg quality and quantity affect disease progression, and that antigen-presenting cell (APC) dynamics play a central role. Notably, Treg therapy combined with APC depletion improves outcomes, especially with strong peptide-induced APC activation.

  • Open Access

    Understanding therapeutic tolerance through a mathematical model of drug-induced resistance

    by Eduardo D. Sontag, Jana L. Gevertz, James Greene, Natacha Comandante-Lou, Samantha Prosperi

    There is growing recognition that phenotypic plasticity enables cancer cells to adapt to various environmental conditions. An example of this adaptability is the persistence of an initially sensitive population of cancer cells in the presence of therapeutic agents. Understanding the implications of this drug-induced resistance is essential for predicting transient and long-term tumor tumor dynamics subject to treatment. This paper introduces a mathematical model of this phenomenon of drug-induced resistance which provides excellent fits to time-resolved in vitro experimental data. From observational data of total numbers of cells, the model unravels the relative proportions of sensitive and resistance subpopulations, and quantifies their dynamics as a function of drug dose. The predictions are then validated using data on drug doses which were not used when fitting parameters. The model is then used, in conjunction with optimal control techniques, in order to discover dosing strategies that might lead to better outcomes as quantified by lower total cell volume.


  • Open Access

    Unveiling Wildfire Dynamics: A Bayesian County-Specific Analysis in California

    by Shreejit Poudyal, Alex Lindquist, Nate Smullen, Victoria York, Ali Lotfi, James Greene, Mohammad Meysami

    Recently, the United States has experienced, on average, costs of USD 20 billion due to natural and climate disasters, such as hurricanes and wildfires. In this study, we focus on wildfires, which have occurred more frequently in the past few years. This paper examines how various factors, such as the PM10 levels, elevation, precipitation, SOX, population, and temperature, can influence the intensity of wildfires differently across counties in California. More specifically, we use Bayesian analysis to classify all counties of California into two groups: those with more wildfires and those with fewer wildfires. The Bayesian model incorporates prior knowledge and uncertainty for a more robust understanding of how these environmental factors impact wildfires differently among county groups. The findings show a similar effect of the SOX, population, and temperature, while the PM10, elevation, and precipitation have different implications for wildfires across various groups.

  • Open Access

    Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach

    by Mackenzie Dalton, Emmanuel Asante-Asamani, James Greene

    The dynamics of insulin and glucose are tightly regulated. The pancreatic islets of Langerhans contain both beta and alpha cells which produce insulin and glucagon, respectively. Insulin is the only hormone in the body that lowers blood glucose levels by acting like a key for glucose to enter cells. Without insulin, cells cannot utilize glucose, their primary source of energy. In contrast, glucagon functions as a hormone which elevates blood glucose levels by promoting the breakdown of glycogen in the liver. Maintaining blood glucose within a safe range is vital since both excessively high and low levels can be life-threatening (hyperglycemia and hypoglycemia, respectively), and these two hormones work together to achieve this balance. In this work we aim to underscore the significance of glucagon in the insulin-glucose regulatory system. We construct a three-compartment mechanistic model that includes insulin, glucose, and glucagon, which is then validated by fitting to publicly available from an intravenous glucose tolerance test (IVGTT). After model validation, we investigate how removing glucose feedback from insulin secretion, as seen in insulin-dependent diabetes, disrupts the regulation of glucose and glucagon. To do this, we simulate the model (a) when insulin secretion is reduced to mimic an insufficient dose of insulin, (b) when the peak of insulin action is delayed mimicking a dosing delay of insulin, and (c) when both occur simultaneously. Lastly, we test different half-lives of insulin to evaluate how an increased half-life of manufactured insulin may further disrupt the system. We find that when insulin secretion is decreased, glucagon still responds to high glucose levels by decreasing glucagon production. This suggests that in cases of type 2 diabetes, where glucagon secretion is elevated despite high levels of glucose, a lack of insulin response may not be the sole cause for glucagon dysfunction. We also find that delaying insulin secretion increases the risk of a hypoglycemic event through a suppression of glucagon production. Initially, the spike in glucose causes glucagon secretion to be reduced; this is then followed by the delay in insulin peak which then continues to suppress glucagon despite blood glucose levels falling, leading to a lack of response by glucagon and a subsequent hypoglycemic event. Furthermore, we find that a higher half-life of insulin causes it to remain longer in the blood stream, inhibiting glucagon’s response to severely low glucose levels (glucose levels less than 3.9 mmol/L). This sheds light on why patients taking exogenous insulin, which has a longer half-life than endogenous insulin, may have difficulty recovering from hypoglycemic events. Hence, our model suggests that keeping the half-life of exogenous insulin below 10 minutes and administering it immediately after meals could help reduce the risk of hypoglycemic events in patients with type 1 or insulin dependent diabetes. Overall, we highlight how a disruption in the feedback between insulin and glucose not only alters blood glucose levels, but also glucagon response, which may lead to further disruption of the system.

  • Open Access

    Utilizing logistic regression to compare risk factors in disease modeling with imbalanced data: a case study in vitamin D and cancer incidence

    by Mohammad Meysami, Vijay Kumar, McKayah Pugh, Samuel Thomas Lowery, Shantanu Sur, Sumona Mondal, James M. Greene

    Imbalanced data, a common challenge encountered in statistical analyses of clinical trial datasets and disease modeling, refers to the scenario where one class significantly outnumbers the other in a binary classification problem. This imbalance can lead to biased model performance, favoring the majority class, and affecting the understanding of the relative importance of predictive variables. Despite its prevalence, the existing literature lacks comprehensive studies that elucidate methodologies to handle imbalanced data effectively. In this study, we discuss the binary logistic model and its limitations when dealing with imbalanced data, as model performance tends to be biased towards the majority class. We propose a novel approach to addressing imbalanced data and apply it to publicly available data from the VITAL trial, a large-scale clinical trial that examines the effects of vitamin D and Omega-3 fatty acid to investigate the relationship between vitamin D and cancer incidence in sub-populations based on race/ethnicity and demographic factors such as body mass index (BMI), age, and sex. Our results demonstrate a significant improvement in model performance after our undersampling method is applied to the data set with respect to cancer incidence prediction. Both epidemiological and laboratory studies have suggested that vitamin D may lower the occurrence and death rate of cancer, but inconsistent and conflicting findings have been reported due to the difficulty of conducting large-scale clinical trials. We also utilize logistic regression within each ethnic sub-population to determine the impact of demographic factors on cancer incidence, with a particular focus on the role of vitamin D. This study provides a framework for using classification models to understand relative variable importance when dealing with imbalanced data.


  • Open Access

    Minimizing the infected peak utilizing a single lockdown: a technical result regarding equal peaks

    by James M. Greene, Eduardo D. Sontag

    Due to the usage of social distancing as a means to control the spread of the novel coronavirus disease COVID-19, there has been a large amount of research into the dynamics of epidemiological models with time-varying transmission rates. Such studies attempt to capture population responses to differing levels of social distancing, and are used for designing policies which both inhibit disease spread but also allow for limited economic activity. One common criterion utilized for the recent pandemic is the peak of the infected population, a measure of the strain placed upon the health care system; protocols which reduce this peak are commonly said to ‘flatten the curve.” In this work, we consider a very specialized distancing mandate, which consists of one period of fixed length of distancing, and addresses the question of optimal initiation time. We prove rigorously that this time is characterized by an equal peaks phenomenon: the optimal protocol will experience a rebound in the infected peak after distancing is relaxed, which is equal in size to the peak when distancing is commenced. In the case of a non-perfect lockdown (i.e. disease transmission is not completely suppressed), explicit formulas for the initiation time cannot be computed, but implicit relations are provided which can be pre-computed given the current state of the epidemic. Expected extensions to more general distancing policies are also hypothesized, which suggest designs for the optimal timing of non-overlapping lockdowns.